Who is sponsoring NCT05053048?

NCT05053048 is sponsored by Kantonsspital Baselland Bruderholz.

What drugs are being tested in NCT05053048?

Interventions in NCT05053048: SL-PLUS-Stem for total hip arthroplasty.

What condition does NCT05053048 study?

NCT05053048 studies Hip Osteoarthritis.

Is NCT05053048 still recruiting?

NCT05053048 is currently completed. Last updated 22 September 2021.

Last reviewed 2021-09-22 · How we verify

NCT05053048

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of an Alumina Free Device Surface on BMD in Patients Implanted With an SL-PLUS™ Femoral Stem for THA

Completed NA Last updated 22 September 2021

What this trial tests

NA trial testing SL-PLUS-Stem for total hip arthroplasty in Hip Osteoarthritis in 45 participants. Completed in 31 May 2012.

Timeline

1 August 2006

Primary endpoint
30 September 2008

31 May 2012

Quick facts

Lead sponsor	Kantonsspital Baselland Bruderholz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	45
Start date	1 August 2006
Primary completion	30 September 2008
Estimated completion	31 May 2012

Drugs / interventions tested

SL-PLUS-Stem for total hip arthroplasty

Conditions studied

Hip Osteoarthritis — all drugs for Hip Osteoarthritis →

Sponsor

Kantonsspital Baselland Bruderholz

Who can join

18 and older, any sex, with Hip Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alumina particles from the grit blasting of Ti-alloy stems for hip arthroplasty are suspected to contribute to aseptic loosening. An alumina-reduced stem surface was hypothesized to improve osseointegration and show comparable short-term outcomes to those of a standard stem.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Unexpected early loosening of rectangular straight femoral Zweymüller stems with an alumina-reduced surface after total hip arthroplasty-a prospective, double-blind, randomized controlled trial.
Moret CS, Masri SE, Schelker BL, Friederich NF, et al · · 2024 · cited 2× · PMID 38430413 · DOI 10.1186/s10195-023-00743-1

Verify or expand the search:

Other recruiting trials for Hip Osteoarthritis

Currently open trials in the same condition.

NCT07330999 — Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults · NA · recruiting
NCT07327931 — PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults · NA · recruiting
NCT07288983 — PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery · NA · recruiting
NCT07327372 — PENG Block With Dexmedetomidine in Older Adults · NA · recruiting
NCT07347041 — Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05053048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kantonsspital Baselland Bruderholz
Last refreshed: 22 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05053048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing